Sanofi-Aventis opts out of diabetes deal with Metabolex
This article was originally published in Scrip
Executive Summary
Sanofi has returned the rights to the type 2 diabetes drug, MBX-2982, to Metabolex, opting out of a deal that could have been worth $375 million to the biotech company.